Maurizio Fava

Maurizio Fava's AcademicInfluence.com Rankings

Maurizio Fava

Philosophy

#2708

World Rank

#4538

Historical Rank

Logic

#733

World Rank

#1253

Historical Rank

philosophy Degrees

Maurizio Fava

Biology

#3192

World Rank

#4919

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Maurizio Fava's Degrees

Doctorate Medicine University of Padua
PhD Psychiatry University of Padua

Why Is Maurizio Fava Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Maurizio Fava's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. (2006) (3196)
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. (2006) (2419)
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report (2006) (1928)
Major depressive disorder (2016) (1913)
Diagnosis and definition of treatment-resistant depression (2003) (1131)
Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. (2009) (1006)
A mega-analysis of genome-wide association studies for major depressive disorder (2013) (979)
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. (2006) (951)
Medication augmentation after the failure of SSRIs for depression. (2006) (940)
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. (2004) (933)
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. (2008) (739)
Definition and epidemiology of treatment-resistant depression. (1996) (696)
Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. (2008) (664)
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder (2006) (593)
Depression and public health: an overview. (2002) (568)
The STAR*D project results: A comprehensive review of findings (2007) (567)
Remissions in Maternal Depression and Child Psychopathology: A STAR*D-Child Report (2006) (539)
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. (2003) (535)
Harmonization of cortical thickness measurements across scanners and sites (2017) (534)
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) (2003) (499)
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial (1998) (499)
Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging (2006) (496)
Residual symptoms in depressed patients who respond acutely to fluoxetine. (1999) (455)
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. (2006) (437)
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. (2009) (437)
Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder (2006) (424)
Effect of age at onset on the course of major depressive disorder. (2007) (410)
Genomewide Association for Major Depressive Disorder: A possible role for the presynaptic protein Piccolo (2008) (410)
Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence (2010) (405)
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. (2006) (399)
The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach (2003) (387)
Weight gain and antidepressants. (2000) (366)
Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study (2000) (364)
An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report (2006) (359)
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD (2009) (343)
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study (2008) (340)
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. (2016) (334)
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. (2006) (327)
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. (2011) (322)
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. (2007) (320)
Anxiety disorders in major depression. (2000) (315)
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D (2004) (301)
Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents (2007) (294)
Folate, vitamin B12, and homocysteine in major depressive disorder. (1997) (294)
Quality of life assessments in major depressive disorder: a review of the literature. (2004) (293)
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. (2016) (292)
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. (2006) (291)
The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. (2006) (279)
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. (2010) (273)
Illness Progression, Recent Stress, and Morphometry of Hippocampal Subfields and Medial Prefrontal Cortex in Major Depression (2014) (269)
QT interval and antidepressant use: a cross sectional study of electronic health records (2013) (266)
Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. (2002) (266)
Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. (2005) (256)
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. (2000) (250)
Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches (2008) (249)
Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants (2009) (245)
15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. (2005) (237)
Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment. (1993) (236)
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. (2012) (228)
The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? (2004) (226)
Major depressive subtypes and treatment response (1997) (225)
Daytime sleepiness and insomnia as correlates of depression. (2004) (224)
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. (2007) (223)
Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. (1994) (223)
Major Depressive Disorder (2000) (223)
Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. (2013) (219)
Statistical harmonization corrects site effects in functional connectivity measurements from multi‐site fMRI data (2018) (215)
Psychopharmacologic treatment of pathologic aggression. (1997) (212)
Timing of onset of antidepressant response with fluoxetine treatment. (2000) (212)
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. (2007) (208)
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) (2019) (206)
Depression and Folate Status in the US Population (2003) (205)
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) (2018) (203)
A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. (2006) (198)
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. (2010) (197)
Rating Scales for Depression (2009) (192)
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. (2008) (190)
Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. (2016) (190)
Validation of the Patient Health Questionnaire-9 for depression screening among Chinese Americans. (2008) (190)
The STAR*D study: treating depression in the real world. (2008) (186)
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. (2005) (185)
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment (2003) (182)
Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. (1997) (181)
Prenatal antidepressant exposure is associated with risk for attention deficit-hyperactivity disorder but not autism spectrum disorder in a large health system (2014) (178)
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. (2009) (173)
Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study (2009) (173)
Predictors of Mood Response to Acute Tryptophan Depletion: A Reanalysis (2002) (172)
Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. (1995) (171)
A Double‐Blind, Randomized, Pilot Dose‐Finding Study of Maca Root (L. Meyenii) for the Management of SSRI‐Induced Sexual Dysfunction (2008) (171)
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. (2011) (170)
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. (2008) (170)
The Importance of Irritability as a Symptom of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (2009) (168)
Interruption of selective serotonin reuptake inhibitor treatment (2000) (168)
Augmentation and combination strategies in treatment-resistant depression. (2001) (163)
Adaptation of Dialectical Behavior Therapy Skills Training Group for Treatment-Resistant Depression (2008) (160)
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. (2004) (159)
Elevated Anxiety Sensitivity Index scores in patients with major depression: Correlates and changes with antidepressant treatment. (1995) (157)
What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension (2006) (157)
Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial (2012) (157)
Ventromedial prefrontal cortex and amygdala dysfunction during an anger induction positron emission tomography study in patients with major depressive disorder with anger attacks. (2004) (155)
Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. (2003) (155)
"Anger attacks": possible variants of panic and major depressive disorders. (1990) (154)
Frontal EEG predictors of treatment outcome in major depressive disorder (2009) (154)
Children of currently depressed mothers: a STAR*D ancillary study. (2006) (154)
Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. (1997) (152)
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. (2016) (147)
Strengthening clinical effectiveness trials: Equipoise-stratified randomization (2001) (147)
Sex differences in response to citalopram: a STAR*D report. (2009) (146)
Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses (2004) (146)
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. (2000) (145)
Cortical Thickness Abnormalities in Cocaine Addiction—A Reflection of Both Drug Use and a Pre-existing Disposition to Drug Abuse? (2008) (144)
Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder (2008) (144)
Order of onset of substance abuse and depression in a sample of depressed outpatients. (1999) (144)
Evaluation of Opioid Modulation in Major Depressive Disorder (2014) (143)
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. (2007) (143)
Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine (2002) (142)
Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice (2006) (142)
Neural Substrates of Attentional Bias for Smoking-Related Cues: An fMRI Study (2010) (141)
A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder (2005) (138)
RELATIONSHIP BETWEEN SLEEP DISTURBANCE AND DEPRESSION, ANXIETY, AND FUNCTIONING IN COLLEGE STUDENTS (2013) (137)
Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors (2006) (137)
Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. (2004) (136)
Tolerability issues during long-term treatment with antidepressants. (2004) (135)
An Open Trial of Oral Sildenafilin Antidepressant-Induced Sexual Dysfunction (1998) (135)
Anger attacks in depressed outpatients and their response to fluoxetine (1998) (134)
Sensitivity of the six‐item Hamilton Depression Rating Scale (1997) (134)
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. (2009) (133)
Genome-wide association study of suicide attempts in mood disorder patients. (2010) (132)
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. (2010) (132)
Test–retest reliability of freesurfer measurements within and between sites: Effects of visual approval process (2015) (132)
Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective Chart Review (2000) (129)
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. (2007) (128)
Development of a Brief Screening Instrument: The HANDS (1999) (127)
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. (2005) (126)
Insomnia in Patients With Depression: A STAR*D Report (2010) (125)
Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications (1997) (124)
Childhood trauma history is linked to abnormal brain connectivity in major depression (2019) (122)
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ) (2010) (121)
The impact of medical comorbidity on acute treatment in major depressive disorder. (2003) (120)
Depression, IV: STAR*D treatment trial for depression. (2003) (120)
Reliability and Validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (2009) (120)
A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. (2014) (119)
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. (2004) (119)
Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. (2010) (118)
Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. (2001) (118)
An electroencephalographic signature predicts antidepressant response in major depression (2019) (117)
CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER (2014) (116)
Patterns of personality disorder comorbidity in early-onset versus late-onset major depression. (1996) (116)
Factors that differentiate early vs. later onset of major depression disorder (2004) (116)
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study) (2012) (116)
Gender differences in personality disorders. (1995) (116)
Anger attacks in patients with depression. (1999) (115)
New approaches to the treatment of refractory depression. (2000) (115)
Course and treatment of atypical depression. (1998) (115)
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. (2000) (114)
Comparing anxiety disorders and anxiety-related traits in bipolar disorder and unipolar depression. (2003) (114)
An electronic health records study of long-term weight gain following antidepressant use. (2014) (114)
The prevalence of sleep-related eating disorder in psychiatric and non-psychiatric populations (1999) (114)
Microstructural Abnormalities in Subcortical Reward Circuitry of Subjects with Major Depressive Disorder (2010) (113)
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder (2009) (113)
Basal ganglia choline levels in depression and response to fluoxetine treatment: An in vivo proton magnetic resonance spectroscopy study (1997) (112)
Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. (2017) (111)
Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance (2005) (111)
Clinical and demographic factors associated with DSM-IV melancholic depression. (2006) (110)
Attention deficit hyperactivity disorder in childhood among adults with major depression (1996) (109)
Italian Validation of the Symptom Rating Test (SRT) and Symptom Questionnaire (SQ)* (1983) (109)
A Meta-Analysis of Early Sustained Response Rates Between Antidepressants and Placebo for the Treatment of Major Depressive Disorder (2006) (109)
Management of nonresponse and intolerance: switching strategies. (2000) (108)
Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment (2008) (108)
Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. (2014) (107)
Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. (2010) (105)
Depression with anger attacks. (1998) (105)
Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. (2011) (105)
Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. (2010) (104)
S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. (2014) (104)
Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis (2007) (103)
Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D (2008) (102)
Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis (2010) (102)
Folate in depression: efficacy, safety, differences in formulations, and clinical issues. (2010) (102)
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. (2008) (101)
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. (2019) (100)
Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. (2008) (100)
Illness Beliefs of Depressed Chinese American Patients in Primary Care (2004) (100)
Predictors of relapse in a prospective study of fluoxetine treatment of major depression. (2006) (100)
The Anxiety Sensitivity Index: Item Analysis and Suggestions for Refinement (2001) (100)
S-Adenosyl-L-Methionine (SAMe) as an Adjunct for Resistant Major Depressive Disorder: An Open Trial Following Partial or Nonresponse to Selective Serotonin Reuptake Inhibitors or Venlafaxine (2004) (100)
Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study (2008) (99)
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder (2008) (99)
Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial (2018) (97)
Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. (2006) (96)
Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. (2007) (95)
Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders (2015) (95)
When should a trial of fluoxetine for major depression be declared failed? (2003) (94)
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. (2001) (94)
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. (2009) (94)
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants (2003) (94)
The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. (2004) (93)
Obesity among outpatients with major depressive disorder. (2005) (93)
Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study (2018) (93)
Suicidality and fluoxetine: is there a relationship? (1991) (93)
Guidelines for the recognition and management of mixed depression. (2017) (93)
Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder (2009) (93)
Hypothyroidism and hyperthyroidism in major depression revisited. (1995) (92)
S-adenosyl-methionine in depression: A comprehensive review of the literature (2003) (92)
Nortriptyline for treatment-resistant depression. (2003) (91)
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder (2008) (90)
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. (2005) (90)
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder (2008) (90)
The prevalence of compulsive eating and exercise among college students: An exploratory study (2009) (90)
Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. (2009) (89)
Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. (2016) (89)
Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. (1996) (89)
Remissions in Maternal Depression and Child Psychopathology (2013) (88)
Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians (2000) (88)
Personality disorder comorbidity with major depression and response to fluoxetine treatment. (1994) (88)
STAR*D (2009) (88)
Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. (2002) (88)
Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia (2002) (87)
USE OF THE CHINESE VERSION OF THE BECK DEPRESSION INVENTORY FOR SCREENING DEPRESSION IN PRIMARY CARE (2002) (87)
Pain in depression: STAR*D study findings. (2007) (86)
Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients (2009) (86)
Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. (1992) (85)
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report (2008) (85)
Somatic symptoms, depression, and antidepressant treatment. (2002) (84)
Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. (2015) (84)
Anger attacks in depression (1998) (83)
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. (2007) (83)
An open trial of methyltetrahydrofolate in elderly depressed patients. (1993) (81)
Change in emotional processing during a dialectical behavior therapy-based skills group for major depressive disorder. (2009) (81)
Fenfluramine challenge in unipolar depression with and without anger attacks (2000) (81)
Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study (2016) (81)
Prevalence and correlates of anger attacks: a two site study. (1996) (80)
The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. (2008) (80)
Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study (2015) (79)
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. (2005) (79)
Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. (2004) (78)
Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. (2006) (78)
Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation (2017) (78)
A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: Relationship to treatment response and clinical severity (1997) (78)
Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. (1989) (77)
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. (2012) (76)
Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder (2002) (76)
Outcome Definitions and Predictors in Depression (1998) (75)
Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms (2008) (75)
Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes (2006) (75)
A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity (1998) (75)
Sexual functioning and SSRIs. (2002) (74)
Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. (2002) (74)
A survey of prescribing practices in the treatment of depression (2002) (74)
What Did STAR✫D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression (2012) (73)
The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. (2003) (73)
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. (2013) (73)
Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. (2010) (73)
Cardiovascular risk factors in depression. The role of anxiety and anger. (1996) (71)
Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder (2017) (71)
DOCOSAHEXANOIC ACID AND ω-3 FATTY ACIDS IN DEPRESSION (2000) (71)
Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. (2007) (70)
Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression (2007) (70)
Depression hostility and anxiety in hyperprolactinemic amenorrhea. (1981) (70)
Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. (2006) (70)
Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder (2009) (70)
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. (2011) (69)
Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study (2005) (69)
Culturally sensitive collaborative treatment for depressed chinese americans in primary care. (2010) (69)
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. (2016) (69)
Anger attacks in eating disorders (1995) (69)
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies (2017) (69)
Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder (2014) (69)
The antidepressant potential of oral S‐adenosyl‐l‐methionine * (1990) (69)
Associations among smoking, anhedonia, and reward learning in depression. (2014) (69)
Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder (1999) (68)
Tryptophan depletion in SSRI-recovered depressed outpatients (2001) (68)
A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. (1997) (68)
Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. (2012) (67)
Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. (2003) (66)
Fatigue as a residual symptom of depression. (2011) (66)
An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. (2005) (66)
A Brief Review of Antidepressant Efficacy, Effectiveness, Indications, and Usage for Major Depressive Disorder (2008) (65)
The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. (2000) (65)
Circulating microRNAs as biomarkers for depression: Many candidates, few finalists. (2017) (65)
Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine (2004) (64)
Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans. (2004) (64)
A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. (1998) (64)
Gender differences in Axis I comorbidity among depressed outpatients. (1996) (64)
Preadult onset vs. adult onset of major depressive disorder: a replication study (2007) (64)
Personality disorders and depression (2002) (63)
Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder (2014) (63)
Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence. (2009) (63)
Complicated grief among individuals with major depression: prevalence, comorbidity, and associated features. (2011) (63)
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. (1999) (63)
The Pharmacologic Management of SSRI-Induced Side Effects: A Survey of Psychiatrists (2002) (62)
Greater Extracellular Free Water in First-Episode Psychosis Predicts Better Neurocognitive Functioning (2017) (62)
Depression and Suicidal Ideation in College Students (2012) (62)
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. (1995) (62)
Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. (2014) (62)
Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder (2005) (62)
Additional findings on the association between anxiety sensitivity and hypochondriacal concerns: examination of patients with major depression. (1998) (62)
Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study (2006) (61)
HOPELESSNESS AND SUICIDAL IDEATION IN OUTPATIENTS WITH TREATMENT-RESISTANT DEPRESSION: PREVALENCE AND IMPACT ON TREATMENT OUTCOME (2003) (61)
An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. (2012) (61)
Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. (2002) (61)
Do atypical features affect outcome in depressed outpatients treated with citalopram? (2010) (60)
A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders (2008) (60)
Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea (2017) (59)
The combination of duloxetine and bupropion for treatment‐resistant major depressive disorder (2006) (59)
Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. (2012) (59)
Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks (2006) (59)
Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. (1999) (59)
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial (2012) (58)
Prospective studies of adverse events related to antidepressant discontinuation. (2006) (58)
Impact of medical comorbid disease on antidepressant treatment of major depressive disorder (2004) (58)
Somatic symptoms in treatment-resistant depression (2003) (58)
Dysfunctional attitudes in major depression. Changes with pharmacotherapy. (1994) (57)
Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. (2004) (57)
Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. (2007) (57)
Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram) (2007) (57)
Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. (2010) (57)
Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. (2020) (56)
Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder (1992) (56)
Inflammatory cytokines in major depressive disorder: A case–control study (2017) (56)
Childhood psychopathology retrospectively assessed among adults with early onset major depression. (1994) (56)
Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. (1999) (56)
Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. (1996) (55)
Norms for depressed patients for the California verbal learning test: associations with depression severity and self-report of cognitive difficulties. (1994) (55)
Body dysmorphic disorder in outpatients with major depression. (2002) (55)
S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life (2018) (55)
The future of psychopharmacology of depression. (2010) (54)
Dissociable cortico-striatal connectivity abnormalities in major depression in response to monetary gains and penalties (2014) (54)
Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-l-methionine (1995) (54)
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies (2013) (54)
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder (2007) (54)
Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. (2008) (54)
Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment. (1993) (54)
Second-tier natural antidepressants: review and critique. (2011) (53)
Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. (2018) (53)
Anhedonia in melancholic and non-melancholic depressive disorders. (2015) (53)
Amyotrophic lateral sclerosis disease progression model (2014) (53)
Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. (2011) (53)
Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. (2010) (52)
Internet Game Addiction, Depression, and Escape From Negative Emotions in Adulthood: A Nationwide Community Sample of Korea (2017) (52)
Eating disorder symptomatology in major depression. (1997) (52)
CLINICAL OUTCOMES IN MEASUREMENT‐BASED TREATMENT (COMET): A TRIAL OF DEPRESSION MONITORING AND FEEDBACK TO PRIMARY CARE PHYSICIANS (2012) (52)
Using online social media, Facebook, in screening for major depressive disorder among college students (2013) (52)
Gender, Depressive Symptoms and Patterns of Alcohol Use among College Students (2010) (52)
Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. (2012) (51)
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. (2008) (51)
Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder (2009) (51)
Tridimensional Personality Questionnaire Factors in Major Depressive Disorder: Relationship to Anxiety Disorder Comorbidity and Age of Onset (2005) (51)
Differences in depressive symptoms between Korean and American outpatients with major depressive disorder (2014) (51)
Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment (2007) (51)
Low-dose Transdermal Testosterone Augmentation Therapy Improves Depression Severity in Women (2009) (51)
Understanding the effects of emotional reactivity on depression and suicidal thoughts and behaviors: Moderating effects of childhood adversity and resilience. (2019) (51)
A critical overview of the pharmacologic management of treatment-resistant depression. (2007) (50)
Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. (2010) (50)
Brain white-matter hyperintensities and treatment outcome in major depressive disorder (2006) (50)
Paraquat Prohibition and Change in the Suicide Rate and Methods in South Korea (2015) (50)
The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. (2014) (50)
Acceptability of second-step treatments to depressed outpatients: a STAR*D report. (2007) (50)
Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response. (2017) (49)
Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. (2008) (49)
Tai Chi Treatment for Depression in Chinese Americans: A Pilot Study (2012) (48)
PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Depression and Renal Disease (2005) (48)
Fluoxetine treatment of anger attacks: a replication study. (1996) (48)
Prevalence of major depressive disorder among Chinese-Americans in primary care. (2004) (48)
Redefining Affective Disorders: Relevance for Drug Development (2008) (48)
A computational analysis of flanker interference in depression (2015) (48)
Assuring that double-blind is blind. (2010) (48)
Folinic Acid (Leucovorin) as an Adjunctive Treatment for SSRI-Refractory Depression (2002) (48)
Continuation and Maintenance Treatments of Major Depressive Disorder (1994) (48)
Lactate infusion induces panic attacks in patients with premenstrual syndrome. (1992) (48)
Feasibility and effectiveness of telepsychiatry services for chinese immigrants in a nursing home. (2009) (48)
Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). (2004) (47)
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. (2011) (47)
Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. (2011) (47)
Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants (2012) (47)
Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls (2015) (47)
A meta-analysis of clinical trials comparing milnacipran, a serotonin–norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder (2007) (47)
Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression (2017) (47)
Feelings of worthlessness, traumatic experience, and their comorbidity in relation to lifetime suicide attempt in community adults with major depressive disorder. (2014) (47)
Treatment resistant depression and Axis I co-morbidity (2001) (47)
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. (2011) (46)
Research Designs and Methods in Psychiatry (1992) (46)
The pro-inflammatory profile of depressed patients is (partly) related to obesity. (2015) (46)
Relationship Between Obesity and Depression: Characteristics and Treatment Outcomes With Antidepressant Medication (2013) (46)
Gender Differences in Hostility Among Depressed and Medical Outpatients (1995) (46)
Use of functional imaging across clinical phases in CNS drug development (2013) (45)
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder (2008) (45)
Serum Cholesterol in Treatment-Resistant Depression (2003) (45)
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies (2013) (45)
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. (2015) (45)
The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. (2011) (45)
A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER (2015) (45)
S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders (1996) (45)
Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II) (2005) (44)
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. (2020) (44)
Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. (2014) (44)
Dichotic Listening before and after Fluoxetine Treatment for Major Depression: Relations of Laterality to Therapeutic Response (1996) (44)
Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. (2008) (44)
An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder (2008) (44)
A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder (2006) (44)
Factors that distinguish college students with depressive symptoms with and without suicidal thoughts. (2013) (44)
Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. (2006) (44)
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. (2002) (44)
Depression with physical symptoms: treating to remission. (2003) (44)
Clinical and Genetic Dissection of Anger Expression and CREB1 Polymorphisms in Major Depressive Disorder (2007) (44)
Cognitive therapy for anxious depression in STAR(*) D: what have we learned? (2012) (44)
A New Population‐Enrichment Strategy to Improve Efficiency of Placebo‐Controlled Clinical Trials of Antidepressant Drugs (2010) (43)
Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? (1996) (43)
Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. (2008) (43)
Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder (2018) (43)
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment. (2007) (43)
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. (2002) (43)
Using electronic medical records to determine the diagnosis of clinical depression (2011) (43)
A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. (2015) (42)
Pharmacological approaches to the treatment of residual symptoms (2006) (42)
Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. (2007) (41)
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies (2018) (41)
Treatment Approaches to Major Depressive Disorder Relapse (2002) (41)
Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies (2009) (41)
Web-Based Depression Screening and Psychiatric Consultation for College Students: A Feasibility and Acceptability Study (2014) (40)
Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. (2015) (40)
Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants. (2008) (40)
Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. (2008) (40)
NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients (2002) (40)
An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding (2002) (39)
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine (2010) (39)
Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. (2017) (38)
Illness beliefs of Chinese American immigrants with major depressive disorder in a primary care setting. (2015) (38)
Life Event, Mood, and Cognitive Predictors of Perceived Stress Before and After Treatment for Major Depression (1997) (38)
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder (2010) (38)
A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder. (2011) (38)
Patterns of improvement in depressive symptoms with fluoxetine treatment. (1995) (38)
Physical fitness and perceived stress. Relationships with coronary artery disease risk factors. (1995) (38)
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. (2011) (38)
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome (2010) (37)
Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). (2014) (37)
Psychosocial functioning in patients with treatment resistant depression (2004) (37)
High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. (1992) (37)
Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial (2019) (37)
Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. (2003) (37)
A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial (2018) (37)
Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. (2007) (37)
Severe Depression (2001) (37)
Relationships between major depressive disorder and comorbid anxiety and personality disorders. (2005) (36)
Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine (2003) (36)
Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms (2008) (36)
Is there a placebo problem in antidepressant trials? (2005) (36)
Hostility changes following antidepressant treatment: relationship to stress and negative thinking. (1996) (36)
Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment (2000) (36)
Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder (1989) (36)
Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. (1999) (36)
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder (2008) (36)
Serum cholesterol and serotonergic function in major depressive disorder (2003) (36)
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. (2004) (35)
Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression (2008) (35)
Clinical Global Impression Scale—Severity of Fatigue (2014) (35)
Acceptability of second-step treatments to depressed outpatients: A STAR*D report (2007) (35)
Integrating cognitive therapy and pharmacotherapy in the treatment and prophylaxis of depression: a novel approach. (1994) (35)
Comparison of Quality of Life Measures in a Depressed Population (2007) (35)
Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). (2009) (35)
Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement (2018) (35)
Personality disorders and perceived stress in major depressive disorder (2008) (35)
Stressful life events and affective disorders inhibit pulsatile LH secretion in hypothalamic amenorrhea (1993) (34)
A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression (1998) (34)
Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day (2003) (34)
Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder (2012) (34)
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. (2019) (34)
Perceived and actual obesity in childhood and adolescence and risk of adult depression (2012) (34)
Hypochondriacal Concerns in Depressed Outpatients (1996) (34)
Psychosomatic aspects of hyperprolactinemia. (1983) (34)
Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. (2013) (33)
Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine (2006) (33)
Augmenting antidepressants with folate: a clinical perspective. (2007) (33)
A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women (2015) (33)
THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS (2015) (33)
Development and validation study of the Smartphone Overuse Screening Questionnaire (2017) (33)
Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial (2015) (32)
Treatment-Resistant Depression and Axis II Comorbidity (2002) (32)
Neuroendocrine Correlates of the Type a Behavior Pattern: A Review and New Hypotheses (1988) (32)
Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses. (2005) (32)
Bereavement and the diagnosis of major depressive episode in the National Epidemiologic Survey on Alcohol and Related Conditions. (2012) (32)
Oral glycine administration increases brain glycine/creatine ratios in men: A proton magnetic resonance spectroscopy study (2009) (31)
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression (2018) (31)
Are study dropouts different from completers? (1996) (31)
Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. (1999) (31)
Revisiting the role of the insula and smoking cue-reactivity in relapse: A replication and extension of neuroimaging findings. (2017) (30)
An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder: Comparison of Switching Versus Initiating Treatment Approaches (2005) (30)
Adjunctive atomoxetine for residual fatigue in major depressive disorder. (2006) (30)
Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment. (2002) (30)
Treatment approaches to major depressive disorder relapse. Part 1: dose increase. (2002) (30)
Reliability and validity of the Symptoms of Depression Questionnaire (SDQ) (2014) (30)
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study (2016) (30)
Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder (2008) (30)
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder (2017) (30)
Compulsive alcohol use and other high-risk behaviors among college students. (2011) (30)
Sociodemographic Predictors of Response to Antidepressant Treatment (1997) (29)
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder (2007) (29)
Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial (2018) (29)
Development and evaluation of a multimodal marker of major depressive disorder (2018) (29)
Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. (2011) (29)
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients (2005) (29)
The impact of diabetes on depression treatment outcomes. (2010) (29)
Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. (2006) (29)
Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I) (2005) (29)
Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial. (2020) (29)
Recognizing and engaging depressed Chinese Americans in treatment in a primary care setting (2006) (29)
Management of Major Depression in the Primary Care Setting (2001) (29)
Closing the efficacy-effectiveness gap: translating both the what and the how from randomized controlled trials to clinical practice. (2009) (29)
Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in MEasurement-based Treatment (COMET) trial. (2012) (29)
Perceived Stress and Cognitive Vulnerability Mediate the Effects of Personality Disorder Comorbidity on Treatment Outcome in Major Depressive Disorder: A Path Analysis Study (2007) (28)
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. (2018) (28)
Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. (2012) (28)
Prospective association between major depressive disorder and leukocyte telomere length over two years (2018) (28)
Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. (2004) (28)
An open-label pilot study of oral S-adenosyl-L-methionine in major depression: interim results. (1988) (28)
Life events impact in patients with secondary amenorrhoea. (1994) (28)
Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR*D trial (2009) (28)
The thyrotropin response to thyrotropin‐releasing hormone as a predictor of response to treatment in depressed outpatients (1992) (28)
Outpatients with DSM-III-R versus DSM-IV melancholic depression. (1996) (28)
Management of depression relapse: re-initiation of duloxetine treatment or dose increase. (2006) (28)
Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. (2012) (27)
A Pilot, Randomized Controlled Study of Tai Chi With Passive and Active Controls in the Treatment of Depressed Chinese Americans. (2017) (26)
Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals (2019) (26)
Fluoxetine treatment of depressed patients with comorbid anxiety disorders (2002) (26)
Axis III disorders in treatment-resistant major depressive disorder (2003) (26)
Major Depressive Disorder With Anger Attacks and Subcortical MRI White Matter Hyperintensities (2007) (26)
Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome (2011) (26)
Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study (2017) (26)
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. (2021) (26)
Recurrent, Robust and Scalable Patterns Underlie Human Approach and Avoidance (2010) (26)
Diurnal mood variation in outpatients with major depressive disorder (2009) (26)
A comparison of structural connectivity in anxious depression versus non-anxious depression. (2017) (26)
Melancholic features and hostility are associated with suicidality risk in Asian patients with major depressive disorder. (2013) (26)
Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive Disorder (2007) (26)
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. (2012) (26)
Massachusetts General Hospital Comprehensive Clinical Psychiatry (2015) (26)
A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain. (2017) (26)
Treatment Approaches to Major Depressive Disorder Relapse (2002) (26)
Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder (2015) (25)
Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. (2015) (25)
A study of the effectiveness of telepsychiatry-based culturally sensitive collaborative treatment of depressed Chinese Americans (2011) (25)
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. (2012) (25)
Discovery and replication of cerebral blood flow differences in major depressive disorder (2019) (25)
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder (2004) (25)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). (2019) (24)
Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. (2005) (24)
Identifying Risk for Attrition during Treatment for Depression (2009) (24)
Melancholia and axis II comorbidity. (2002) (24)
Anxiety Symptoms Questionnaire (ASQ): development and validation (2019) (24)
Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study (2017) (24)
Pharmacotherapy for Depression and Treatment-Resistant Depression (2010) (24)
What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? (2012) (24)
Antidepressant Response and Well-Being in Pre-, Peri- and Postmenopausal Women with Major Depressive Disorder Treated with Fluoxetine (2005) (24)
A Double-blind, Placebo-Controlled Study of the Impact of Galantamine on Anterograde Memory Impairment During Electroconvulsive Therapy (2013) (24)
Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. (2022) (24)
Development of a clinical global impression scale for fatigue. (2012) (24)
Brain Regulation of Emotional Conflict Predicts Antidepressant Treatment Response for Depression (2019) (24)
Behavioral and Emotional Disturbances in the Offspring of Depressed Parents with Anger Attacks (2003) (23)
Family history of depression and therapeutic outcome: findings from STAR*D. (2009) (23)
Massachusetts General Hospital SAFER Criteria for Clinical Trials and Research (2013) (23)
Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. (2011) (23)
Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. (2011) (23)
Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. (2004) (23)
Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor Treatment: A Suicide Assessment Methodology Study Report (2010) (23)
Switching to bupropion in fluoxetine-resistant major depressive disorder. (2003) (23)
Metabolic Assessment of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Pooled Analysis of 2 Studies (2009) (23)
Psychological and behavioral benefits of a stress/type A behavior reduction program for healthy middle-aged army officers. (1991) (23)
Incentive salience: novel treatment strategies for major depression (2013) (23)
Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. (2015) (22)
Use of treatment algorithms for depression. (2006) (22)
The relationship of depression to dissociation in patients with bulimia nervosa. (1993) (22)
The overlap between personality disorders and major depressive disorder (MDD). (2004) (22)
Predictors of placebo response in bipolar depression (2015) (22)
Childhood parental death and lifetime suicide attempt of the opposite-gender offspring in a nationwide community sample of Korea. (2013) (21)
Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. (2019) (21)
Online recovery support meetings can help mitigate the public health consequences of COVID-19 for individuals with substance use disorder (2020) (21)
Relationship Between Residual Symptoms of Depression and Self-reported Cognitive Impairment (2010) (21)
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. (2004) (21)
Obsessive-Compulsive Symptoms as a Risk Factor for Suicidality in U.S. College Students. (2016) (21)
Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. (1990) (21)
The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. (2007) (21)
The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study. (2008) (21)
Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. (2016) (20)
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. (2020) (20)
DEFINITION AND RESISTANT DEPRESSION EPIDEMIOLOGY OF TREATMENT (1996) (20)
Screening for Suicide Risk in the College Population (2015) (20)
The promise and challenges of drug repurposing in psychiatry (2018) (20)
Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. (2007) (20)
Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression (2018) (20)
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. (2007) (20)
Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. (2018) (20)
Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. (2011) (20)
A pilot study of acupuncture monotherapy in patients with major depressive disorder. (2012) (20)
College students with depressive symptoms with and without fatigue: Differences in functioning, suicidality, anxiety, and depressive severity. (2015) (20)
Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. (2014) (20)
Major Depressive Disorder with Anger Attacks and Cardiovascular Risk Factors (2007) (20)
Augmentation and combination strategies for complicated depression. (2009) (20)
Early drop-outs, late drop-outs and completers Differences in the continuation phase of a clinical trial (2002) (20)
Randomized, controlled, participant‐ and rater‐blind trial of pharmacogenomic test‐guided treatment versus treatment as usual for major depressive disorder (2020) (20)
Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study (2016) (20)
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. (2012) (20)
The aims and design of the sequenced treatment alternatives to relieve depression (STAR*D) study (2005) (20)
Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. (2012) (20)
Correlations between perceived stress and depressive symptoms among depressive outpatients (1992) (20)
Use of treatment algorithms for depression. (2006) (20)
Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder (2013) (19)
Clinically Relevant Findings from STAR*D (2008) (19)
Switching treatments for complicated depression. (2010) (19)
Psychological, behavioral and biochemical risk factors for coronary artery disease among American and Italian male corporate managers. (1992) (19)
Linking major depression and the neural substrates of associative processing (2016) (19)
Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: Implications for mechanisms of change. (2015) (19)
Sleep quality, posttraumatic stress, depression, and human errors in train drivers: a population-based nationwide study in South Korea. (2014) (19)
Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC Study. (2017) (19)
Neural Predictors of Successful Brief Psychodynamic Psychotherapy for Persistent Depression (2014) (19)
Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder (2018) (19)
Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. (2005) (19)
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? (2020) (19)
Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study (2015) (19)
Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine (2004) (19)
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. (2009) (19)
An Open Study of Aripiprazole and Escitalopram for Psychotic Major Depressive Disorder (2009) (19)
A randomized controlled dosing study of Iyengar yoga and coherent breathing for the treatment of major depressive disorder: Impact on suicidal ideation and safety findings. (2018) (19)
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study. (2016) (19)
Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. (2003) (19)
A survey of prescribing preferences in the treatment of refractory depression: recent trends. (2001) (19)
From depression to anxiety, and back (2017) (18)
Alcohol-induced disinhibition is associated with impulsivity, depression, and suicide attempt: A nationwide community sample of Korean adults. (2018) (18)
Gender Differences in Somatic Symptoms and Current Suicidal Risk in Outpatients with Major Depressive Disorder (2016) (18)
A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. (2012) (18)
Dysfunctional attitudes and personality disorder comorbidity during long‐term treatment of MDD (2007) (18)
Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice (2016) (18)
Celebrity Suicides and Their Differential Influence on Suicides in the General Population: A National Population-Based Study in Korea (2015) (18)
Physiologic benefits of a stress reduction program for healthy middle-aged Army officers. (1993) (18)
The Effectiveness of Telepsychiatry-Based Culturally Sensitive Collaborative Treatment for Depressed Chinese American Immigrants: A Randomized Controlled Trial. (2016) (18)
Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders (2010) (18)
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. (2020) (18)
Assessing response to treatment and recognizing residual depressive symptoms. (2014) (18)
Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. (1999) (18)
Relationship between placebo response rate and clinical trial outcome in bipolar depression. (2016) (17)
The Treatment of Depressed Chinese Americans Using Qigong in a Health Care Setting: A Pilot Study (2013) (17)
Pattern of Depressive Symptoms in Parkinson's Disease (2009) (17)
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. (2021) (17)
The Quick Inventory of Depressive Symptomatology, Clinician Rated and Self-report: A Psychometric Assessment in Chinese Americans With Major Depressive Disorder (2012) (17)
Tachyphylaxis in major depressive disorder: A review of the current state of research. (2019) (17)
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning (2016) (17)
Response rates to fluoxetine in subjects who initially show no improvement. (2011) (17)
Drug interactions in psychopharmacology. (1993) (17)
Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial. (2019) (17)
Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. (2021) (17)
A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression (2011) (17)
Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence (2018) (17)
Long‐term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder (2008) (17)
Placebo non‐response measure in sequential parallel comparison design studies (2015) (17)
Perceptual asymmetry, plasma cortisol, and response to treatment in depressed outpatients (1991) (17)
The Engagement Interview Protocol (EIP): improving the acceptance of mental health treatment among Chinese immigrants (2011) (17)
Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. (2015) (17)
The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study (2011) (17)
Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. (2020) (16)
Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment (2012) (16)
PREDICTORS OF STABLE PERSONALITY DISORDER DIAGNOSES IN OUTPATIENTS WITH REMITTED DEPRESSION (2002) (16)
Association Between Stigma and Depression Outcomes Among Chinese Immigrants in a Primary Care Setting. (2016) (16)
Improvement in Subjective and Objective Neurocognitive Functions in Patients With Major Depressive Disorder: A 12-Week, Multicenter, Randomized Trial of Tianeptine Versus Escitalopram, the CAMPION Study (2014) (16)
Handbook of chronic depression : diagnosis and therapeutic management (2003) (16)
Salience network coupling is linked to both tobacco smoking and symptoms of attention deficit hyperactivity disorder (ADHD). (2018) (16)
Assessing anxious features in depressed outpatients (2011) (16)
Changes in Depressive Symptoms and Social Functioning in the Sequenced Treatment Alternatives to Relieve Depression Study (2011) (16)
Childhood Trauma, Parental Death, and Their Co-occurrence in Relation to Current Suicidality Risk in Adults: A Nationwide Community Sample of Korea (2014) (16)
The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study (2015) (16)
The Effects of Tai Chi on Sleep Quality in Chinese American Patients With Major Depressive Disorder: A Pilot Study (2018) (16)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression: Is There a Relationship to Leptin Levels? (2015) (16)
Clinical characteristics of depressed patients with comorbid diabetes mellitus (2006) (16)
Correlates of Irritability in College Students With Depressive Symptoms (2013) (16)
Risk of Suicidality in Depression with Serotonergic Antidepressants (2000) (16)
A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. (2008) (16)
Race/Ethnicity and Other Social Determinants of Psychological Well-being and Functioning in Mental Health Clinics (2014) (16)
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents (2023) (15)
Psychological correlates of hyperprolactinemia in males. (1982) (15)
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. (2019) (15)
The absence of depressive symptoms is not the presence of wellness: Validation of the Clinical Positive Affect Scale (2012) (15)
Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. (2010) (15)
Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder (2016) (15)
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2018) (15)
EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE‐BLIND RANDOMIZED TRIAL (2012) (15)
The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause (2019) (15)
Increased amygdala-visual cortex connectivity in youth with persecutory ideation (2019) (15)
Long-Term Use of Fluoxetine in Bulimia Nervosa: A Retrospective Study (1990) (15)
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder (2009) (15)
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder (2019) (15)
Prolactin and stress (1987) (15)
Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. (2007) (15)
Self-Management of Depression: A Manual for Mental Health and Primary Care Professionals (2009) (14)
Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse (2020) (14)
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD) (2018) (14)
Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. (2002) (14)
Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression (2018) (14)
Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction (2007) (14)
Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study. (2015) (14)
Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. (1995) (14)
Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder (2019) (14)
Evaluating Patient Acceptability of a Culturally Focused Psychiatric Consultation Intervention for Latino Americans with Depression (2014) (14)
Sexual Disinhibition during Treatment with a Benzodiazepine: A Case Report (1991) (14)
Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. (2019) (14)
Effects of transcranial photobiomodulation with near‐infrared light on sexual dysfunction (2018) (14)
Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine (2010) (14)
Cortical thickness is not associated with current depression in a clinical treatment study (2017) (14)
Assessing depression and factors possibly associated with depression during the course of Parkinson's disease. (2011) (14)
Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. (2004) (14)
The Role of Cognitive-Behavioral Therapy and Fluoxetine in Prevention of Recurrence of Major Depressive Disorder (2010) (14)
Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-analysis (2010) (14)
Prolactin, aggression and hostility: a discussion of recent studies. (1984) (14)
Effect of Korean Red Ginseng in individuals exposed to high stress levels: a 6-week, double-blind, randomized, placebo-controlled trial (2018) (14)
Does Psychiatry Residency Training Reflect the “Real World” of Psychiatry Practice? A Survey of Residency Graduates (2007) (13)
Cynicism, hostility, and suicidal ideation in depressed outpatients. (1996) (13)
A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking in Females (2011) (13)
The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report (2009) (13)
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder (2020) (13)
A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. (2005) (13)
Outcomes of Recognizing Depressed Chinese American Patients in Primary Care (2005) (13)
Association Between Smoking and Heart Rate Variability Among Individuals with Depression (2013) (13)
Elevated Amygdala Activity in Young Adults With Familial Risk for Depression: A Potential Marker of Low Resilience. (2019) (13)
Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). (2014) (13)
The evaluation of a culturally appropriate, community-based lifestyle intervention program for elderly Chinese immigrants with chronic diseases: a pilot study. (2014) (13)
Guarding the Gate (2017) (13)
Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia (2019) (13)
Outcomes of an online computerized cognitive behavioral treatment program for treating chinese patients with depression: A pilot study. (2017) (13)
Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos. (2013) (13)
Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder (2009) (12)
Switching to Bupropion in Fluoxetine-Resistant Major Depressive Disorder (2003) (12)
5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response (2010) (12)
Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report (2006) (12)
Mood Disorders: Major Depressive Disorder and Dysthymic Disorder (2008) (12)
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study (2010) (12)
Are thymoleptic-responsive "anger attacks" a discrete clinical syndrome? (1993) (12)
Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. (2015) (12)
Personality Disorders and the Trimensional Personality Questionnaire Factors in Major Depressive Disorder (2005) (12)
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (2019) (12)
Acupuncture for major depressive disorder: has its efficacy been disproved? (2007) (12)
Major depressive disorder with psychosis-like symptoms among Latinos. (2012) (12)
T3 Blood Levels and Treatment Outcome in Depression (2001) (11)
Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial (2019) (11)
Binge eating, trauma, and suicide attempt in community adults with major depressive disorder (2018) (11)
Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study. (2020) (11)
Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. (2020) (11)
Cross-Cultural Aspects of Depression Management in Primary Care (2012) (11)
Review of Suicide Prevention Programs: Massachusetts, United States, in Comparison with Seoul (2015) (11)
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). (2022) (11)
Are nutritional supplements ready for prime time? (2008) (11)
Altered temporal, but intact spatial, features of transient network dynamics in psychosis (2021) (11)
Comprar Massachusetts General Hospital Comprehensive Clinical Psychiatry | Scott Rauch | 9780323047432 | Mosby (2008) (11)
Genome-wide association for major depressive disorder (2012) (11)
Increased morbidity of major depressive disorder after thyroidectomy: a nationwide population-based study in South Korea. (2019) (11)
Dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. (1987) (11)
John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials (2020) (11)
Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended‐Release and Long‐Acting Injectable Paliperidone (2016) (11)
Risks of Completed Suicide of Community Individuals with ICD-10 Disorders Across Age Groups: A Nationwide Population-Based Nested Case-Control Study in South Korea (2019) (11)
Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress (2018) (10)
Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial? (2012) (10)
Prolactin, cortisol, and antidepressant treatment. (1988) (10)
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. (2004) (10)
Launching a resiliency group program to assist frontline clinicians in meeting the challenges of the COVID-19 pandemic: Results of a hospital-based systems trial (2020) (10)
Pattern of depressive symptoms in Parkinson's disease. (2009) (10)
Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder (2016) (10)
Depression and hostility in hyperprolactinemia (1982) (10)
Adjunctive Pregabalin in Partial Responders With Major Depressive Disorder and Residual Anxiety (2013) (10)
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies (2017) (10)
Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI (2011) (10)
PS89. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study (2015) (10)
Symptoms of Anxiety and Irritability in Patients with Major Depressive Disorder (2016) (10)
Prolactin, amitriptyline, and recovery from depression (2004) (10)
Monoaminergic‐based Pharmacotherapy for Depression (2005) (10)
Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial (2002) (10)
Fluoxetine versus sertraline and paroxetine in major depression: Long-term changes in weight (1998) (9)
What is the overlap between subjective and objective cognitive impairments in MDD? (2018) (9)
Self-Management of Depression (2009) (9)
Risks of suicide attempts after prescription of zolpidem in people with depression: A nationwide population study in South Korea. (2020) (9)
Buspirone therapy for Type A behavior, hostility, and perceived stress in cardiac patients. (1993) (9)
Psychopharmacology of Pathologic Aggression (1993) (9)
Partial responders to antidepressant treatment: switching strategies. (2009) (9)
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adole (2021) (9)
Effectiveness of the Relaxation Response-Based Group Intervention for Treating Depressed Chinese American Immigrants: A Pilot Study (2014) (9)
The Mini-Mental State Examination among adult outpatients with major depressive disorder. (1995) (9)
Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis (2017) (9)
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study (2019) (9)
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study (2020) (9)
Paranoid Ideation Without Psychosis Is Associated With Depression, Anxiety, and Suicide Attempts in General Population. (2019) (9)
Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. (2019) (9)
Depression monitoring and patient behavior in the Clinical Outcomes in MEasurement-Based Treatment (COMET) trial. (2014) (9)
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study (2021) (9)
Evidence for the use of l-methylfolate combined with antidepressants in MDD. (2011) (9)
Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. (2020) (8)
Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients (2014) (8)
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis (2020) (8)
Complementary and Alternative Medicine in Major Depressive Disorder (2009) (8)
Compulsive use of alcohol among college students (2013) (8)
Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial (2014) (8)
All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment. (2019) (8)
Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. (2020) (8)
Insured and non-insured depressed outpatients: how do they compare? (2007) (8)
PS153. Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial (2015) (8)
Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. (2019) (8)
Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability (2017) (8)
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression (2013) (8)
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. (2020) (8)
Community-Delivered Heated Hatha Yoga as a Treatment for Depressive Symptoms: An Uncontrolled Pilot Study. (2019) (7)
A comparison of symptoms following treatment interruption: Evidence from a randomized, double-blind trial with fluoxetine, sertraline, and paroxetine (1998) (7)
Examining the efficacy of d-cycloserine to augment therapeutic learning in depression. (2016) (7)
Lifetime suicidal ideation and attempt in adults with full major depressive disorder versus sustained depressed mood. (2016) (7)
Anxious attachment is associated with heightened responsivity of a parietofrontal cortical network that monitors peri-personal space (2021) (7)
Cross-Disorder Genomics Data Analysis Elucidates a Shared Genetic Basis Between Major Depression and Osteoarthritis Pain (2021) (7)
Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder. (2015) (7)
The Possible Antianxiety and Mood-Stabilizing Effects of Rufinamide (2010) (7)
Phase IIb Trial of an &agr;7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence (2018) (7)
Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. (2018) (7)
The relationship between age and personality disorders in depressed outpatients. (1995) (7)
Can electronic health records revive central nervous system clinical trials? (2018) (7)
A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response (2015) (7)
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder (2021) (6)
Are Dependency and Self-Criticism Risk Factors for Major Depressive Disorder? (1997) (6)
Fatigue across the CNS spectrum: a clinical review (2014) (6)
The effect of sildenafil on quality of life. (2013) (6)
Loss of sexual interest and premenstrual mood change in women with postpartum versus non-postpartum depression: A nationwide community sample of Korean adults. (2016) (6)
Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression (2000) (6)
Introduction: Optimizing Treatment Outcome in Depression (2000) (6)
Genetic Association of Attention-Deficit/Hyperactivity Disorder and Major Depression With Suicidal Ideation and Attempts in Children: The Adolescent Brain Cognitive Development Study (2021) (6)
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. (2020) (6)
Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. (2016) (6)
The Inflammatory Hypothesis of Depression (2012) (6)
A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed (2003) (6)
Hyperprolactinemia and psychological distress in women undergoing chronic hemodialysis. (1988) (6)
Ziprasidone augmentation for anxious depression (2016) (6)
Chapter 18 – Psychopharmacologic Issues in the Medical Setting (2004) (6)
Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. (2019) (6)
Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. (2017) (6)
Transmethylation and the central nervous system (1994) (6)
Multiple types of somatic pain increase suicide attempts and depression: A nationwide community sample of Korean adults. (2019) (6)
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. (2017) (6)
Relationship between cannabis use and psychotic experiences in college students (2021) (6)
Optimal dosing of antidepressant drugs. (2019) (6)
CBT Delivered in a Specialized Depression Clinic for College Students with Depressive Symptoms (2018) (5)
Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19-34: A nationwide population study in South Korea. (2020) (5)
The Phenomenology and Epidemiology of Intermittent Explosive Disorder (2011) (5)
Cross-national differences in hypochondriasis symptoms between Korean and American outpatients with major depressive disorder (2016) (5)
The Combination of Buspirone and Bupropion in the Treatment of Depression (2007) (5)
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. (2009) (5)
Comparisons of Subthreshold Versus Full Posttraumatic Stress Disorder Distinguished by Subjective Functional Impairment Among Train Drivers: A Population-Based Nationwide Study in South Korea (2016) (5)
Evaluating the combination of a Brief Motivational Intervention plus Cognitive Behavioral Therapy for Depression and heavy episodic drinking in college students. (2019) (5)
Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder (2003) (5)
Chapter 2 Rating Scales for Depression (2009) (5)
Childhood's Enuresis in the History of Women with Hyperprolactinemic Amenorrhea (1990) (5)
Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study (2020) (5)
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators (2022) (5)
Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review (2020) (5)
Anxiety attacks with or without life-threatening situations, major depressive disorder, and suicide attempt: a nationwide community sample of Korean adults (2018) (5)
Placebo Response as a Latent Characteristic: Application to Analysis of Sequential Parallel Comparison Design Studies (2018) (5)
Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study (2019) (5)
Associations Between Genetic Risk for Adult Suicide Attempt and Suicidal Behaviors in Young Children in the US (2022) (5)
Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis. (2022) (5)
Combined MI + CBT for Depressive Symptoms and Binge Drinking Among Young Adults: Two Case Studies (2013) (5)
The influence of DST and TRH test administration on depression assessments: A controlled study (1993) (5)
Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults. (2020) (5)
Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine. (2007) (5)
Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. (2020) (5)
Using the Electronic Medical Record to Examine Racial and Ethnic Differences in Depression Diagnosis and Treatment in a Primary Care Population (2012) (5)
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors (2022) (5)
Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. (2013) (4)
Depression in college students in Bombay: A study of 2273 individuals (2002) (4)
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. (2020) (4)
Reply to Folate Supplementation: Is It Safe and Effective? (2009) (4)
Does folic acid interfere with lamotrigine? (2016) (4)
Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response (2022) (4)
9 – Mood-Disordered Patients (2010) (4)
Novel Study Designs for Clinical Trials in Mood Disorders (2015) (4)
Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. (2019) (4)
Comparison of Academic and Nonacademic Sites in Multi-Center Clinical Trials (2012) (4)
Academic Highlights: Review of the Pharmacologic Management of Depression.[CME] (2006) (4)
Hormone therapy and the decreased risk of dementia in women with depression: a population-based cohort study (2022) (4)
[Anger outbursts in unipolar depressive disorders]. (1997) (4)
Problem‐solving ability and comorbid personality disorders in depressed outpatients (2006) (4)
High Bodyweight Variability Increases Depression Risk in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea (2021) (4)
A Double-Blind Randomized Controlled Trial of Ethyl- Eicosapentaenoate (EPA-E) for Major Depressive Disorder (2010) (4)
Erratum: The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine (International Journal of Neuropsychopharmacology (2005) DOI: 10.1017/S1461145705005195) (2005) (4)
An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report. (1988) (4)
A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: Comparing patients who recently discontinued an ssri with those on no recent antidepressant treatment (2004) (4)
Preface Transmethylation and the central nervous system (1994) (4)
Evidence for folate in combination with antidepressants at initiation of therapy. (2010) (4)
Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study (2020) (4)
Using complementary and alternative medicines for depression. (2010) (4)
Differences in cognitive factors between “true drug” versus “placebo pattern” response to fluoxetine as defined by pattern analysis (2006) (4)
Examining the role of race and ethnicity in relapse rates of major depressive disorder. (2011) (4)
Comparison of suicide attempts in individuals with major depressive disorder with and without history of subthreshold hypomania: A nationwide community sample of Korean adults✰,✰✰. (2019) (3)
Pharmacological Treatment of Major Depressive Disorder: A Review (2009) (3)
A commentary on: statistical inference problems in sequential parallel comparison designs (2019) (3)
A survey of five antidepressant properties influencing clinician’s treatment choices in MDD (2007) (3)
Early‐onset depression and the emotional and behavioral characteristics of offspring (2003) (3)
114 An Assessment of QTc Effects With SPN-812 (Extended-Release Viloxazine) in Healthy Adults (2020) (3)
How to write a study protocol : a primer for the clinician (1992) (3)
Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial (2020) (3)
P-2-84 A pilot study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia (1995) (3)
How can we make measures of psychotic depression symptoms more clinically useful? (2014) (3)
Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. (2013) (3)
Corrigendum to ''Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder'' [J. Affect. Disord. 187 (2015) 183–187] (2016) (3)
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. (2021) (3)
Design and Methods of the Korean National Investigations of 70,000 Suicide Victims Through Police Records (The KNIGHTS Study) (2019) (3)
Female reproductive life cycle and hormones: methodology to improve clinical trials. (2013) (3)
The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder (2015) (3)
Moderators of a resiliency group intervention for frontline clinicians during the COVID-19 pandemic (2021) (3)
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial. (2022) (3)
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling (2022) (3)
Voice response system to measure healthcare costs: a STAR*D report. (2009) (3)
14-105 Preclinical and clinical evidence for antidepressant properties of the COMT inhibitor tolcapone (1997) (3)
Sex Differences in the Association between Heavy Drinking and Behavioral Distress Tolerance and Emotional Reactivity Among Non-Depressed College Students (2018) (3)
A Cross-Sectional Study of Private Psychiatric Practices under a Single-Payer Health Care System (1997) (3)
Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial (2021) (3)
Model‐Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response (2019) (3)
Bioavailability of S-Adenosyl Methionine and Impact on Response in a Randomized Controlled Trial in Major Depressive Disorder (2014) (3)
Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder? (2017) (3)
Self-Management of Depression: The use of self-management for depression (2009) (3)
50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results (2019) (3)
Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant. (2017) (3)
Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder". (2000) (3)
Serotonin Transporter Gene Polymorphism and Personality Traits in Primary Alcohol Dependence (2004) (3)
Fluoxetine versus sertraline and paroxetine in major depression: Long‐term changes in weight (2000) (2)
Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report (2009) (2)
Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. (2022) (2)
Lessons Learned: Implementation of a Culturally Focused Psychiatric Consultation Service for Latino Americans and Asian Americans (2015) (2)
Massachusetts General Hospital Psychopharmacology and Neurotherapeutics (2015) (2)
Comprar Pharmacotherapy for depression and treatment-resistant depression | Papakostas, G.I. | 9789814287586 | World Scientific Publishing (2010) (2)
High body weight variability is associated with increased risk of depression: a nationwide cohort study in South Korea. (2022) (2)
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Non-Suicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. (2022) (2)
Associations Between Smoking, Alcohol Consumption, Physical Activity and Depression in Middle-Aged Premenopausal and Postmenopausal Women (2021) (2)
Association of smartphone overuse with depression, anxiety, and other addictive behaviors: A nationwide community sample of Korean adults (2021) (2)
Does the alleviation of painful physical symptoms associated with depression lead to higher remission rates (2003) (2)
Impaired Oxygenation of the Prefrontal Cortex During Verbal Fluency Task in Young Adults With Major Depressive Disorder and Suicidality: A Functional Near-Infrared Spectroscopy Study (2022) (2)
Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial. (2008) (2)
Increased metabolic variability is associated with newly diagnosed depression: A nationwide cohort study. (2021) (2)
Obsessive Thought, Compulsive Behavior, and Their Associations With Suicide Ideation and Attempts and Major Depressive Disorder (2021) (2)
Bullying, Psychological, and Physical Trauma During Early Life Increase Risk of Major Depressive Disorder in Adulthood: A Nationwide Community Sample of Korean Adults (2022) (2)
Brain Ventricle Morphology as Predictor of Treatment-Response- Findings From the EMBARC-Study (2021) (2)
Onset of response to fluoxetine treatment as assessed by the symptom questionnaire (2000) (2)
Augmentation and combination strategies to treat the residual symptoms of major depressive disorder. (2007) (2)
Patient primary language in a culturally focused intervention for Latino Americans with depression. (2018) (2)
Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. (2019) (2)
A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder (2016) (2)
Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. (2009) (2)
Randomized, Double-Blind Study of Fixed-Dose Intranasal Esketamine Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression (2019) (2)
Epidemiologic evidence concerning the bereavement exclusion in major depression. (2012) (2)
Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study. (2017) (2)
Release bias in accessing medical records in clinical trials: a STAR*D report (2009) (2)
Association between pre-pregnancy tobacco smoking and postpartum depression: A nationwide cohort study. (2022) (2)
904: Sildenafil Treatment of Serotonergic Antidepressant Associated Sexual Dysfunction in Women with Major Depression Disorder in Remission: An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial with 8-Week Open-Label Continuation (2006) (2)
The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder (2009) (2)
NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. (2020) (2)
Conducting Clinical Research Remotely for Individuals with Traumatic Brain Injury (TBI) and Depression during the COVID-19 Pandemic: Transitioning from In-Person to Remote Implementation. (2021) (2)
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study (2017) (2)
34 – Psychopharmacology in the Medical Setting (2011) (2)
Review of the pharmacologic management of depression. (2006) (2)
Is It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again? (2022) (2)
Easing the Burden of Treatment-Resistant Depression: (Academic Highlights) (2009) (1)
STAR*D Clarification (2006) (1)
F27. EFFICACY OF MONTHLY EXTENDED-RELEASE RISPERIDONE INJECTIONS (RBP-7000) FOR THE TREATMENT OF SCHIZOPHRENIA: AN ANALYSIS OF INDIVIDUAL PANSS ITEMS (2019) (1)
Major depressive disorder with psychosis-like symptoms in Latinos: treatment with and without antipsychotic augmentation (2015) (1)
Psychoticism and Paranoid Ideation in Patients With Nonpsychotic Major Depressive Disorder: Prevalence, Response to Treatment, and Impact on Short- and Long-Term Treatment Outcome (2010) (1)
Depression: addressing partial response after first-line antidepressant treatment. (2014) (1)
Diminished frontal pole volume and functional connectivity in young adults with high suicidality. (2022) (1)
Self-Management of Depression: Care management of depression: treatment of depression in primary care and the need for a multidisciplinary approach (2009) (1)
A multi-pronged investigation of option generation using depression, PET and modafinil. (2022) (1)
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. (2022) (1)
Mirtazapine versus paroxetine in elderly patients with anxious depression (2002) (1)
Validation of a global assessment measure for fatigue (2012) (1)
Remission of Maternal Depression and Children’s Psychopathology—Reply (2006) (1)
Dr Gilman and colleagues reply. (2013) (1)
Suicidal ideation in a college population: Prevalence and predictors (2001) (1)
P.1.095 Conditional probability of remission at 8 weeks given early global improvement in major depressive disorder (MDD) (2003) (1)
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators (2023) (1)
P.2.a.027 Cross cultural aspects of depression among college students (2007) (1)
Chapter 8 – Mood-Disordered Patients (2004) (1)
The United States index of socioeconomic deprivation for individuals (USiDep) (2022) (1)
P.2.f.009 The efficacy of levomilnacipran extended-release (ER) in the treatment of patients with depression-associated fatigue symptoms (2014) (1)
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants (2022) (1)
Type A behavior pattern (TABP) and dehydroepiandrosterone-sulfate (DHEA-S) (1988) (1)
Suppression and acceptance in unipolar depression: Short-term and long-term effects on emotional responding. (2021) (1)
Easing the burden of treatment-resistant depression. (2009) (1)
True drug response versus placebo pattern response to fluoxetine: Differences in cognitive factors (1999) (1)
Constricted semantic relations in acute depression. (2022) (1)
P.032 A phase-2, double-blind, placebo-controlled, sequential parallel comparison design study of efficacy and safety of adjunctive pimavanserin in major depressive disorder (2019) (1)
Biological Predictors, Moderators, and Mediators of Efficacy (2010) (1)
PET imaging of neurotransmission using direct parametric reconstruction (2020) (1)
Characterizing Cerebral Blood Perfusion and Treatment Outcomes in Atypical and Melancholic Depression (2020) (1)
Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia (2020) (1)
Non-pharmacologic Approaches for Resistant Depression (2010) (1)
A Survey of Antidepressant Prescribing Practices in Major Depression with Comorbid Attention-Deficit Hyperactivity Disorder (2006) (1)
Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. (2023) (1)
Dr. Mischoulon and colleagues reply. (2014) (1)
Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. (2020) (1)
Corrigendum to “Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls” [Psychoneuroendocrinology 58 (2015) 9–22] (2016) (1)
The Impact of Childhood Trauma, Hallucinations, and Emotional Reactivity on Delusional Ideation (2020) (1)
Diagnostic Rating Scales and Psychiatric Instruments (2008) (1)
Pharmacological Strategies for Targeting Residual Symptoms in Depression (2019) (1)
A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire (2022) (1)
342. Fluoxetine versus sertraline and paroxetine in major depression: Safety and efficacy in anxious and nonanxious subgroups (1998) (1)
Self-Management of Depression: Index (2009) (1)
Menstrual-related mood changes in patients with oligomenorrhea. (1994) (1)
Direct Parametric Reconstruction for Improved Characterization of Neurotransmitter Release using Dynamic PET (2018) (1)
P.1.129 Depression and suicidal ideation among college students in Bombay: A study of 1357 individuals (2004) (1)
180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin (2020) (1)
Clinical Positive Affect Scale (2014) (1)
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo (2023) (0)
Personalized Medicine (2018) (0)
Cerebral Blood Perfusion Moderates Treatment Response to Sertraline in Major Depressive Disorder (2019) (0)
Academic Highlights: Enhancing Treatment Response in Depression. [CME] (2004) (0)
Response to Blier letter (2012) (0)
Book Review / Announcements (2002) (0)
Enhancement of Treatment Response in Depression in the Primary Care Setting. (2004) (0)
In reply [11] (2006) (0)
Smartphone Overuse Screening Questionnaire (2018) (0)
Clinical Study Near-Infrared Transcranial Radiation for Major Depressive Disorder : Proof of Concept Study (2015) (0)
S95. Loudness Dependency of Auditory Evoked Potentials (LDAEP) as a Differential Predictor of Antidepressant Treatment Response in Major Depressive Disorder (MDD): Results From the Sertraline/Placebo-Controlled EMBARC Study (2018) (0)
PS281. Lifetime suicidal ideation and attempt in community adults with full major depressive disorder versus only sustained depressed mood (2016) (0)
Corrigendum to "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants" [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1]. (2018) (0)
Psychiatric symptomatology in secondary amenorrhea (1986) (0)
Exploring Gender Differences in the Placebo Response to Major Depressive Disorder (MDD) Using Neuroimaging Techniques (2021) (0)
The Impact of Medicalon Acute Treatment in Major Depressive Disorder (2005) (0)
Cognitive Subtypes of Depression are Associated With Response to Treatment by Sertraline (2020) (0)
PS90. Differences in hypochondriasis between Korean and American outpatients with major depressive disorder (2016) (0)
Występowanie zaburzeń nastroju w rodzinie a cechy dużej depresji: badanie STAR*D (sekwencyjne alternatywy terapeutyczne w leczeniu depresji) (2006) (0)
P.577 ADVANCE: phase 2, randomised, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with negative symptoms of schizophrenia (2020) (0)
Concise Health Risk Tracking Scale (2020) (0)
P.2.a.032 Sleep disturbance and suicidal ideation among college students (2007) (0)
173. The Incremental Predictive Validity of Rostral Anterior Cingulate Cortex Activity in Relation to Treatment Response in Depression: Evidence from the EMBARC Study (2017) (0)
S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive Disorder (2018) (0)
Treating the Whole Patient to Achieve Remission (2004) (0)
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. (2022) (0)
Contents, Vol. 40, 1983 (1983) (0)
Contents Vol. 78, 2009 (2009) (0)
Monoaminergic-Based Strategies: “Single-Acting” Agents (2010) (0)
An O-15 PET study of differential brain activation and peripheral autonomic responses in depressed patients during mood induction (2007) (0)
Screening for Suicide Risk in the College Population (2015) (0)
Reply to Comments by Drs. Bschor and Bauer (2004) (0)
5-Adenosylmethionine ( Ademetionine ) in Psychiatric Disorders Historical Perspective and Current Status (0)
Cerebral Blood Flow Differences in Major Depressive Disorder using Arterial Spin Labeling: Preliminary Results from the EMBARC Study (2013) (0)
464. Phosphorous-31 magnetic resonance spectroscopy of the basal ganglia in depressed subjects (1996) (0)
Pharmacological Approaches to Treatment-Resistant Depression (2008) (0)
PMH51 - HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG COMMUNITY-DWELLING SUBJECTS WITH SCHIZOPHRENIA TREATED WITH RBP-7000 IN A CLINICAL TRIAL SETTING OVER 12 MONTHS (2018) (0)
Test-retest reliability of cortical thickness in a multi-site study (2014) (0)
Brain regulation of emotional conflict predicts antidepressant treatment response for depression (2019) (0)
Future Directions in Treatment Development (2010) (0)
elomere Shortening and Mood Disorders: reliminary Support for a Chronic Stress Model f Accelerated Aging (2006) (0)
181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (2020) (0)
Comment on “Primum non noccere”. (2012) (0)
Pharmacologic Strategies to Enhance Antidepressant Tolerability (2010) (0)
Association Between Ghrelin and Body Weight Trajectory in Individuals With Anorexia Nervosa. (2023) (0)
Association of Anger Attacks With Persistently Elevated Suicidality in Depressed Patients: Do Early Improvements in Irritability Reduce the Risk? (2020) (0)
Conducting Clinical Research Remotely for Individuals with Traumatic Brain Injury (TBI) and Depression during the COVID-19 Pandemic: Transitioning from In-Person to Remote Implementation (Preprint) (0)
Dr. McGrath and Colleagues Reply (2007) (0)
DepressionMonitoringandPatientBehavior intheClinicalOutcomesinMEasurement- BasedTreatment(COMET)Trial (2014) (0)
P.1.241 Symptom questionnaire assessment of depressive symptoms among college students (2003) (0)
Subject Index Vol. 74, 2005 (2005) (0)
Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies. (2022) (0)
The STAR*D Citalopram data revisited with the HAM-D6 and IDS-C6 (2013) (0)
In Memoriam: Joseph Biederman, MD, 1947-2023. (2023) (0)
A Patient with Treatment-resistant Depression Who Achieved Remission with Heated Yoga: A Case Report (2021) (0)
Over-Optimism of Cognitive Behavior Therapy for Schizophrenia (2006) (0)
A Patient With Electroconvulsive Therapy-resistant Major Depressive Disorder With a Full Response to Heated Yoga: A Case Report. (2021) (0)
Contents Vol. 74, 2005 (2005) (0)
Agents Operating on Non-monoaminergic Neurotransmitter Systems (2010) (0)
Dose-Dependent Effects of EPA Supplementation on Plasma Specialized Pro-Resolving Mediators in Major Depressive Disorder Patients with Chronic Inflammation (2020) (0)
Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 301) (2023) (0)
Self-Management of Depression: Self-help: the role of bibliotherapy and computerized psychotherapy in self-management for depression (2009) (0)
Reanalysis of a Phase 3 Trial of a Monthly Extended-Release Risperidone Injection for the Treatment of Acute Schizophrenia (2020) (0)
P.1.242 Gender differences in depressive symptoms among college students in Bombay (2003) (0)
Self-assessment instruments for depression (2009) (0)
Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design (2022) (0)
DETAILED STUDY PROTOCOL TITLE: Omega-3 Fatty Acids for MDD with High Inflammation: A Personalized Approach (2019) (0)
Differentiating chronic depression from personality disorders (2007) (0)
Comprar Self-Management of Depression | Albert Yeung | 9780521710084 | Cambridge University Press (2009) (0)
P.1 .034 Efficacy of mirtazapine vs. SSRls in anxietysymptoms associated with major depression: A pooled data analysis (2004) (0)
Patient Global Impression Scale—Severity of Fatigue (2016) (0)
Ages at menarche and menopause, hormone therapy, and the risk of depression. (2023) (0)
P.2.a.03l A cross-cultural, comparative study of the prevalence and symptom patterns of depression among college students (2009) (0)
Reply to Possible Bipolar Nature of Irritability in Major Depressive Disorder (2005) (0)
P.094 Evaluate effects of pimavanserin on anxious depression in patients with major depressive disorder - secondary analysis of the CLARITY Study (2020) (0)
Increased risk of depression before and after unilateral or bilateral oophorectomy: A self-controlled case series study using a nationwide cohort in South Korea. (2021) (0)
Personalizing Depression Treatment: 2 Clinical Tools; Reliable Diagnosis, Count of Adequate Antidepressant Trials Can Suggest Next Steps (2012) (0)
S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive Disorder (2018) (0)
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl- L -Methionine (SAMe) Vs. Escitalopram in Major Depressive Disorder (2017) (0)
Self-Management of Depression: Cultivating social support: the role of peer support in self-management (2009) (0)
176. Evidence of Differential Changes in Cortical Thickness and Volume Between SSRI and Placebo Treated Patients With Major Depressive Disorder (2018) (0)
Dr. Fava and Colleagues Reply (1995) (0)
Correction to Janes et al. (2009). (2010) (0)
CBT Delivered in a Specialized Depression Clinic for College Students with Depressive Symptoms (2018) (0)
3.4 CHANGES IN AMYGDALA AND HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN SUBCLINICAL PSYCHOSIS: RELATIONSHIP TO SYMPTOM PERSISTENCE, PARANOIA AND ABERRANT SALIENCE (2019) (0)
Symptoms of Depression Questionnaire (2019) (0)
939. Identifying Clinically Relevant Electroencephalography Coherence Patterns in Major Depressive Disorder: Results from the EMBARC Study (2017) (0)
Distinct Predictive Patterns of Antidepressant Response to Sertraline, Placebo and Bupropion using Pre-Treatment Reward Processing as examined through Functional MRI and Deep Learning: Key Results from the EMBARC Study (2020) (0)
Association of obesity and levels of Inflammatory markers on treatment outcome with adjunctive L-methylfolate (Deplin) in major depressive disorder patients who are inadequate responders to selective serotonin reuptake Inhibitors (2015) (0)
Optimizing Treatment Outcome in Depression (2003) (0)
Does n-3 Fatty Acid Supplementation Impact Immune and Clinical Outcomes in Inflammatory Depression? (2020) (0)
Clinical Tools for A Personalized Treatment Strategy in Depression. (2012) (0)
Major Depressive Disorder and Treatment-Resistant Depression (2010) (0)
Predictive Patterns of Antidepressant Response from Pre-Treatment Reward Processing using Functional MRI and Deep Learning: Key Results from the EMBARC Randomized Clinical Trial (2020) (0)
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder. (2023) (0)
Is It Time for Going Beyond the P‐Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive Disorder (2018) (0)
Pharmacotherapy of Relapse/Recurrence Prevention and Treatment (2010) (0)
Relationships among subclinical psychotic symptoms in young adults over time (2022) (0)
Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder (2022) (0)
In Memoriam (2002) (0)
DEPRESSION : Mind and Body Advances in the Understanding and Treatment of Depression and its Physical Symptoms Biological and Psychosocial Correlates of Perimenopausal Depression : Implications for Treatment (2007) (0)
88. ASSOCIATION OF GENETIC SUSCEPTIBILITY TO PAIN AND DEPRESSION WITH SUICIDAL THOUGHTS AND ATTEMPTS IN CHILDREN: ADOLESCENT BRAIN COGNITIVE DEVELOPMENT (ABCD) STUDY (2021) (0)
Depressive disorders among minority and nonminority college students (2002) (0)
S198. Effects of Transcranial Photobiomodulation With Near-Infrared Light on Sexual Dysfunction (2019) (0)
Self-Management of Depression: Self-management of depression using meditation (2009) (0)
An electroencephalographic signature predicts antidepressant response in major depression (2020) (0)
Metabolic-Based and Other Agents (2010) (0)
Early psychiatric referral after attempted suicide helps prevent suicide reattempts: A longitudinal national cohort study in South Korea (2022) (0)
Maintaining Treatment Gains (2010) (0)
Association of Obesity and Levels of Inflammatory Markers on Treatment Outcome with Adjunctive (6S)-5-methyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid (CH3-FH4) in MDD Patients Who are Inadequate Responders to SSRIs (2015) (0)
Transitioning From In-Person to Remote Clinical Research on Depression and Traumatic Brain Injury During the COVID-19 Pandemic: Study Modifications and Preliminary Feasibility From a Randomized Controlled Pilot Study (2021) (0)
P.1.086 Modafinil as antidepressant augmentation therapy in major depressive disorder (2004) (0)
A Phase 2a Double-Blind Randomized Trial of REL-1017 in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire (2022) (0)
Contents Vol. 83, 2014 (2014) (0)
Self-Management of Depression: Preface (2009) (0)
Neuroendocrine-Based Agents (2010) (0)
Correction: Childhood trauma history is linked to abnormal brain connectivity in major depression (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (8582–8590) DOI: 10.1073/pnas.1900801116) (2019) (0)
Putting it all together: applying self-management for depression in your practice (2009) (0)
Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder (2017) (0)
The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder (2022) (0)
Esmethadone-HCl (REL-1017): a promising rapid antidepressant. (2023) (0)
COGNITIVE FUNCTION AS A PROXY OF FINANCIAL DECISION MAKING IN OLDER PRIMARY CARE ADULTS (2017) (0)
Fluoxetine treatment of patients with anxious depression (1998) (0)
Cross-Disorder Genetic Data Analysis Elucidates a Genetic Link Between Osteoarthritis and Major Depression (2021) (0)
Linking major depression and the neural substrates of associative processing (2016) (0)
P.1.031 Gepirone extended release (ER) in patients with anxious depression (2003) (0)
S107. Identifying Characteristics of Placebo Responders in Major Depression From the EMBARC Study (2018) (0)
Contents, Vol. 37, 1982 (1982) (0)
SAT-737 Low-Dose Testosterone Augmentation for Treatment-Resistant Depression in Women: An 8-Week, Two-Site, Randomized, Placebo-Controlled Study (2020) (0)
P.338 Effect of adjunctive pimavanserin on suicidality in patients with major depression: secondary analysis from CLARITY (2020) (0)
Polypharmacy Strategies for Treatment-Resistant Depression (2010) (0)
rain Reactivity to Smoking Cues Prior to moking Cessation Predicts Ability to Maintain obacco Abstinence (0)
First-Line Pharmacotherapy Strategies (2010) (0)
Contents, Vol. 67, 1998 (2012) (0)
P.1.128 Depressive symptoms and suicidal ideationamong college students: A study of 752 students in the Boston area (2004) (0)
341. Fluoxetine versus sertraline and paroxetine in major depression: Safety and efficacy in patients with low and high baseline insomnia (1998) (0)
Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder (2019) (0)
P.2.c.003 A placebo-controlled study of EB-1010, a novel triple re-uptake inhibitor, in patients with major depressive disorder (2011) (0)
Diagnosis and Monitoring Depression View project Clinical Studies : Cooling and Omega-3 fatty Acids View project (2010) (0)
MON-449 Serum Neuroactive Steroid Levels in Postmenopausal Women with Treatment-Resistant Major Depressive Disorder (2019) (0)
Next-Step Treatment Strategies (2010) (0)
Contents, Vol. 62, 1994 (1994) (0)
Response to Marks, Abramowitz, and Spielmans Letter to the Editor (2012) (0)
Neural Circuits Linking Irritability and Anger Attacks in Major Depressive Disorder: Findings From EMBARC Study (2020) (0)
Polypharmacy from the Onset of Treatment (2010) (0)
Physical exercise as a form of self-management for depression (2009) (0)
Contents, Vol. 61, 1994 (2004) (0)
Dr. Trivedi and Colleagues Reply (2006) (0)
S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life (2018) (0)
Hormone therapy and the decreased risk of dementia in women with depression: a population-based cohort study (2022) (0)
Front & Back Matter (2012) (0)
SUN-303 Effects of Open-Label, Adjunctive Ganaxalone Treatment on Resistant Depression in Postmenopausal Women: A Pilot Study (2020) (0)
Monotherapy Strategies for Resistant Depression (2010) (0)
Dose- and time-dependent increase in circulating antiinflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation (2021) (0)
O14. Cerebral Blood Perfusion Predicts Response to Antidepressant Treatment in Major Depressive Disorder (2019) (0)
Brain Ventricle and Choroid Plexus Morphology as Predictor of Treatment Response: Findings from the EMBARC Study (2023) (0)
133. Baseline Functional Connectivity and Cerebral Perfusion Markers of Response to Sertraline Vs. Placebo: A Data-Driven Multi-Modal Neuroimaging Study (2019) (0)
Subject Index Vol. 78, 2009 (2009) (0)
P.2.b.041 Use of independent remote (safer) patient interviews in clinical trials for MDD at European study sites (2016) (0)
Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Nonresponse to Acute Intravenous Ketamine Treatment (2022) (0)
Rising placebo response rates threaten the validity of antipsychotic meta-analyses. (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Maurizio Fava?

Maurizio Fava is affiliated with the following schools:

University of Padua
Massachusetts General Hospital
Harvard University

Maurizio Fava's Academic­Influence.com Rankings

Maurizio Fava's Degrees

Why Is Maurizio Fava Influential?

Maurizio Fava's Published Works

Published Works

What Schools Are Affiliated With Maurizio Fava?

Maurizio Fava's AcademicInfluence.com Rankings